Christopher Hill - Core Laboratories Chief Financial Officer, Senior Vice President
| CLB Stock | USD 15.33 0.07 0.45% |
President
Mr. Christopher S. Hill has served as Chief Financial Officer of Core Laboratories N.V. since June 25, 2018. He served as Chief Financial Officer, Chief Accounting Officer of the Company between May 18, 2018 and June 25, 2018. He was Senior Vice President, Chief Accounting Officer of the Company between April 30, 2015 and May 18, 2018. Since joining the Company in October 2006, Mr. Hill has held various positions including Corporationrationrate Controller Financial Reporting, Corporationrationrate Group Controller and Investor Relations. Prior to joining the Company, he worked at Halliburton from August 2000 to October 2006 as Controller Energy Chemicals of the KBR Division and Corporationrationrate Director of Training and Accounting Research. Mr. Hill worked at Ernst Young from January 1993 until August 2000, where he held the position of Manager his last three years there since 2018.
| Age | 55 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Address | 6316 Windfern Road, Houston, TX, United States, 77040 |
| Phone | 713 328 2673 |
| Web | https://www.corelab.com |
Christopher Hill Latest Insider Activity
Tracking and analyzing the buying and selling activities of Christopher Hill against Core Laboratories stock is an integral part of due diligence when investing in Core Laboratories. Christopher Hill insider activity provides valuable insight into whether Core Laboratories is net buyers or sellers over its current business cycle. Note, Core Laboratories insiders must abide by specific rules, including filing SEC forms every time they buy or sell Core Laboratories'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Christopher Hill over a week ago Acquisition by Christopher Hill of 23607 shares of Core Laboratories subject to Rule 16b-3 |
Core Laboratories Management Efficiency
The company has Return on Asset of 0.0553 % which means that on every $100 spent on assets, it made $0.0553 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1319 %, implying that it generated $0.1319 on every 100 dollars invested. Core Laboratories' management efficiency ratios could be used to measure how well Core Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. At present, Core Laboratories' Return On Capital Employed is projected to slightly decrease based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.1, whereas Return On Tangible Assets are forecasted to decline to 0.06. At present, Core Laboratories' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 236.2 M, whereas Total Assets are forecasted to decline to about 553.5 M.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Grant Bates | MRC Global | 53 | |
| Jay Nutt | ChampionX | 55 | |
| David Isaac | Cactus Inc | 59 | |
| Isaac Joseph | NOV Inc | 67 | |
| Jordan Slator | North American Construction | 54 | |
| Jose Bayardo | NOV Inc | 53 | |
| David Lawrence | Oceaneering International | 64 | |
| Joel Bender | Cactus Inc | 65 | |
| Stephen Tadlock | Cactus Inc | 41 | |
| Raymond Chang | Now Inc | 54 | |
| Helmuth Witulski | Enerflex | N/A | |
| Brian Taylor | Oil States International | 61 | |
| Mark Peterson | Oceaneering International | N/A | |
| Toby Eoff | Now Inc | N/A | |
| Jennifer Whalen | Bristow Group | 51 | |
| Benjamin Palmer | RPC Inc | 60 | |
| Scott Duff | NOV Inc | 52 | |
| G Lawrence | Natural Gas Services | 68 | |
| Daniel Churay | MRC Global | 58 | |
| Micah Foster | Natural Gas Services | 44 | |
| Robert Stein | MRC Global | 60 | |
Management Performance
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0553 |
Core Laboratories Leadership Team
Elected by the shareholders, the Core Laboratories' board of directors comprises two types of representatives: Core Laboratories inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Core. The board's role is to monitor Core Laboratories' management team and ensure that shareholders' interests are well served. Core Laboratories' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Core Laboratories' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gwendolyn MBA, Senior Relations | ||
| J Dumas, Vice President Business Development | ||
| Martha Carnes, Presiding Non-Executive Lead Independent Member of the Supervisory Board | ||
| Lawrence Bruno, Chairman of the Supervisory Board, President, Chief Executive Officer, Chief Operating Officer | ||
| Monique Eeuwijk, Non-Executive Independent Member of the Supervisory Board | ||
| Kevin Daniels, Vice President, Chief Accounting Officer | ||
| Jacobus Schouten, Managing Director | ||
| Christopher Hill, Chief Financial Officer, Senior Vice President | ||
| Kwaku Temeng, Non-Executive Independent Member of the Supervisory Board | ||
| Sow Teo, Treasurer VP | ||
| Gregory Barnett, Non-Executive Independent Member of the Supervisory Board | ||
| Margaret Kempen, Independent Member of the Board of Supervisory Directors | ||
| Mark Tattoli, Senior Vice President General Counsel, Secretary | ||
| Mark Elvig, Senior Vice President, Secretary, and General Counsel | ||
| Harvey Klingensmith, Non-Executive Independent Member of the Supervisory Board | ||
| Michael Straughen, Non-Executive Independent Member of the Supervisory Board | ||
| Gwendolyn Gresham, Senior Vice President Corporate Development and Investor Relations | ||
| Leslie Linklater, Organization, People | ||
| Billy Anthony, President Tools |
Core Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Core Laboratories a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0553 | ||||
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 878.84 M | ||||
| Shares Outstanding | 46.83 M | ||||
| Shares Owned By Insiders | 0.95 % | ||||
| Shares Owned By Institutions | 99.05 % | ||||
| Number Of Shares Shorted | 6.47 M | ||||
| Price To Earning | 101.74 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Core Laboratories NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Oil & Gas Equipment & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Core Laboratories. If investors know Core will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Core Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.896 | Dividend Share 0.04 | Earnings Share 0.66 | Revenue Per Share | Quarterly Revenue Growth 0.008 |
The market value of Core Laboratories is measured differently than its book value, which is the value of Core that is recorded on the company's balance sheet. Investors also form their own opinion of Core Laboratories' value that differs from its market value or its book value, called intrinsic value, which is Core Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Core Laboratories' market value can be influenced by many factors that don't directly affect Core Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Core Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if Core Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Core Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.